Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.

6 Nov 2009

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

SAVI 6-1Mini applicator is the only brachytherapy solution for patients with small breasts, says study

The SAVI™ 6-1Mini breast brachytherapy applicator is the only brachytherapy solution for patients with small breasts, hard-to-reach lumpectomy cavities, or cavities close to the skin surface, according to a new study.

6 Nov 2009

Eclipsys’ Sunrise Enterprise integrated suite of solutions selected by NMMC

Eclipsys Corporation®, The Outcomes Company®, today announced that North Mississippi Medical Center (NMMC), a 650-bed regional referral center located in Tupelo, MS, has selected the Eclipsys’ Sunrise Enterprise™ integrated suite of solutions.

6 Nov 2009

Tobacco companies attempt to block key provisions of new tobacco regulation law, federal judge rejects motion

In a clear victory for public health, a federal judge in Kentucky today rejected a motion by tobacco companies to block key provisions of the new law giving the U.S. Food and Drug Administration (FDA) the power to regulate tobacco products. Specifically, today's decision strongly supports the government's authority to prevent the industry from making health claims about its products without FDA approval.

6 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2009.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.

5 Nov 2009

Evidence continues to grow about green tea's cancer prevention properties

Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.

5 Nov 2009

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

5 Nov 2009

Green tea holds hope for prevention of oral cancer

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

5 Nov 2009

New Merck set to begin global health care operations

Merck & Co., Inc. today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

5 Nov 2009

Oncology News and Research

Further Reading

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

SAVI 6-1Mini applicator is the only brachytherapy solution for patients with small breasts, says study

Eclipsys’ Sunrise Enterprise integrated suite of solutions selected by NMMC

Tobacco companies attempt to block key provisions of new tobacco regulation law, federal judge rejects motion

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

New biosensor device may help in combating cancer

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

American Shared Hospital Services reports financial results for the third quarter of 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

Evidence continues to grow about green tea's cancer prevention properties

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

Green tea holds hope for prevention of oral cancer

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

New Merck set to begin global health care operations

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News